Trump Administration Plans to End Medicare Part D Subsidies, Potentially Raising Drug Costs for Millions of Seniors
核心洞察
The Trump administration intends to eliminate a subsidy program providing $3.6 billion annually to insurers to keep Medicare Part D (搜索) premiums low, ending after 2026.
Roughly 25 million Medicare Part D (搜索) beneficiaries could be affected, with approximately 75% expected to see some increase in their monthly out-of-pocket prescription drug costs.
CMS Administrator Mehmet Oz confirmed the subsidies were scrapped, arguing they are no longer necessary and that beneficiaries will have other low-cost options.
The Trump administration is moving to terminate a subsidy program that has helped hold down premiums for Medicare's prescription drug plans, a decision that could leave millions of seniors facing higher out-of-pocket costs for their medications starting in 2027.
The program, which provides an estimated $3.6 billion in subsidies this year to insurance companies to blunt premium increases for Medicare Part D (搜索) plans, will end after 2026, according to administration officials cited by The Wall Street Journal.
Mehmet Oz, the administrator of the Centers for Medicare & Medicaid Services (搜索), confirmed via social media that the subsidies had been scrapped. He argued that they were no longer necessary and that Medicare beneficiaries would have other options for low-cost prescription drug plans.
Scope of Impact on Beneficiaries
Roughly 25 million people are enrolled in Part D plans, and they will learn about their 2027 rates in the fall. According to a Trump administration official, 25% of Medicare enrollees would see their premiums stay the same, 30% would face an increase of less than $10 to their monthly bill, and 45% would see a monthly increase of between $11 and $20.
The average monthly payment for Part D was roughly $36 in 2026. The administration official claimed that the subsidies had encouraged insurers to raise rates and that there would be other means of keeping premiums low.
Political Timing and Broader Context
The timing of the rate change notices is particularly significant. The New York Times reported that in the weeks leading up to November, Medicare beneficiaries could experience "sticker shock" while shopping for next year's drug plan, when insurers' annual "notice of change" disclosures typically reach Americans' mailboxes. This period coincides with the early-voting window across much of the country ahead of the midterm elections.
The Trump administration has already overseen a price increase for some 700 prescription drugs covered by Part D plans. The move also follows the administration's earlier decision to scrap subsidies for Affordable Care Act customers.
According to a Pew Research Center national poll, Americans expressed greater concern about healthcare costs than any other affordability issue, including the price of gasoline and groceries. The decision comes as President Trump's broader budget proposal is set to reduce Medicare funding by an estimated $500 billion over the next eight years.
The subsidies were originally established during Joe Biden's presidency as part of a broader effort to improve the Medicare Part D (搜索) program, which was created under the George W. Bush administration in 2003. Democrats had historically resisted calls to repeal Part D and instead pursued measures to strengthen it, including the subsidy program now targeted for elimination.